136 related articles for article (PubMed ID: 11569889)
41. Efficacy of single-dose intravenous dolasetron versus ondansetron in the prevention of postoperative nausea and vomiting.
Walker JB
Clin Ther; 2001 Jun; 23(6):932-8. PubMed ID: 11440292
[TBL] [Abstract][Full Text] [Related]
42. [Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Alon E; Biro P
Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 May; 31(4):200-4. PubMed ID: 8704077
[TBL] [Abstract][Full Text] [Related]
43. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
44. A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation.
Orchard PJ; Rogosheske J; Burns L; Rydholm N; Larson H; DeFor TE; Ramsay NK; Weisdorf D
Biol Blood Marrow Transplant; 1999; 5(6):386-93. PubMed ID: 10595816
[TBL] [Abstract][Full Text] [Related]
45. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.
Park JO; Rha SY; Yoo NC; Kim JH; Roh JK; Min JS; Kim BS; Chung HC
Am J Clin Oncol; 1997 Dec; 20(6):569-72. PubMed ID: 9391542
[TBL] [Abstract][Full Text] [Related]
46. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
Kris MG; Pendergrass KB; Navari RM; Grote TH; Nelson AM; Thomas V; Ferguson BB; Allman DS; Pizzo BA; Baker TW; Fernando IJ; Chernoff SB
J Clin Oncol; 1997 May; 15(5):2135-8. PubMed ID: 9164228
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
[TBL] [Abstract][Full Text] [Related]
48. Dolasetron for the prevention of postoperative nausea and vomiting following outpatient surgery with general anaesthesia: a randomized, placebo-controlled study. The Dolasetron PONV Prevention Study Group.
Philip BK; Pearman MH; Kovac AL; Chelly JE; Wetchler BV; McKenzie R; Monk TG; Dershwitz M; Mingus M; Sung YF; Hahne WF; Brown RA
Eur J Anaesthesiol; 2000 Jan; 17(1):23-32. PubMed ID: 10758440
[TBL] [Abstract][Full Text] [Related]
49. [Efficacy of granisetron, a 5-HT3 antagonist, in the prevention of nausea and vomiting induced by conditioning for hematopoietic stem cell transplantation].
Hirabayashi N; Goto S; Morishima Y; Sao H; Matsuyama T; Kodera Y; Yamada H; Horibe K; Yano K; Kojima H; Ogura M; Tanimoto M; Morishita Y; Yazaki M; Utsumi M; Nagata K; Kato Y; Naoe T; Saito H
Rinsho Ketsueki; 1998 Jan; 39(1):21-6. PubMed ID: 9492549
[TBL] [Abstract][Full Text] [Related]
50. The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation.
Barbounis V; Koumakis G; Hatzichristou H; Vassilomanolakis M; Tsoussis S; Efremidis A
Support Care Cancer; 1999 Mar; 7(2):79-83. PubMed ID: 10089087
[TBL] [Abstract][Full Text] [Related]
51. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
[TBL] [Abstract][Full Text] [Related]
52. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.
Spitzer TR; Friedman CJ; Bushnell W; Frankel SR; Raschko J
Bone Marrow Transplant; 2000 Jul; 26(2):203-10. PubMed ID: 10918432
[TBL] [Abstract][Full Text] [Related]
53. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.
Abbott B; Ippoliti C; Bruton J; Neumann J; Whaley R; Champlin R
Bone Marrow Transplant; 1999 Feb; 23(3):265-9. PubMed ID: 10084258
[TBL] [Abstract][Full Text] [Related]
54. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial.
Gebbia V; Cannata G; Testa A; Curto G; Valenza R; Cipolla C; Latteri MA; Gebbia N
Cancer; 1994 Oct; 74(7):1945-52. PubMed ID: 8082100
[TBL] [Abstract][Full Text] [Related]
55. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
56. Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy. The Canadian Dolasetron Study Group.
Warriner CB; Knox D; Belo S; Cole C; Finegan BA; Perreault L
Can J Anaesth; 1997 Nov; 44(11):1167-73. PubMed ID: 9398956
[TBL] [Abstract][Full Text] [Related]
57. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens.
Stiff PJ; Fox-Geiman MP; Kiley K; Rychlik K; Parthasarathy M; Fletcher-Gonzalez D; Porter N; Go A; Smith SE; Rodriguez TE
Biol Blood Marrow Transplant; 2013 Jan; 19(1):49-55.e1. PubMed ID: 22863840
[TBL] [Abstract][Full Text] [Related]
58. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
Siddique R; Hafiz MG; Rokeya B; Jamal CY; Islam A
Mymensingh Med J; 2011 Oct; 20(4):680-8. PubMed ID: 22081189
[TBL] [Abstract][Full Text] [Related]
59. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
[TBL] [Abstract][Full Text] [Related]
60. Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.
Adams LM; Johnson B; Zhang K; Yue L; Kirby LC; Lebowitz P; Stoltz R
Support Care Cancer; 2009 Sep; 17(9):1187-93. PubMed ID: 19205754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]